Aqilion regains rights to TAK1 program
AQILION AB (publ) announces that Aqilion and Merck have decided to terminate the joint development of the TAK1 program. Data generated in the course of the collaboration have altered the risk-benefit profile within the intended indications. Merck will return all rights according to the licensing and collaboration agreement that was entered between the two parties in February 2023.Aqilion will ensure that all data and materials will be transferred to the company and will thereafter do an internal analysis of the options to further develop the program, either within the inflammation area or